These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 32316984)

  • 1. Protocol for a randomised trial testing a community fibrosis assessment service for patients with suspected non-alcoholic fatty liver disease: LOCal assessment and triage evaluation of non-alcoholic fatty liver disease (LOCATE-NAFLD).
    Brain D; O'Beirne J; Hickman IJ; Powell EE; Valery PC; Kularatna S; Tulleners R; Farrington A; Horsfall L; Barnett A
    BMC Health Serv Res; 2020 Apr; 20(1):335. PubMed ID: 32316984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementing the right care in the right place at the right time for non-alcoholic fatty liver disease (NAFLD-RRR study): a study protocol for a community care pathway for people with type 2 diabetes.
    Gracen L; Hayward KL; Aikebuse M; Russell A; O'Beirne J; McPhail S; Irvine KM; Williams S; Valery PC; Powell EE
    BMC Health Serv Res; 2022 Apr; 22(1):487. PubMed ID: 35413987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score.
    Tapper EB; Hunink MG; Afdhal NH; Lai M; Sengupta N
    PLoS One; 2016; 11(2):e0147237. PubMed ID: 26905872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and rationale of the INSYTE study: A randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal microbiota in non-alcoholic fatty liver disease.
    Scorletti E; Afolabi PR; Miles EA; Smith DE; Almehmadi A; Alshathry A; Moyses HE; Clough GF; Wright M; Patel J; Bindels L; Delzenne NM; Calder PC; Byrne CD
    Contemp Clin Trials; 2018 Aug; 71():113-123. PubMed ID: 29787859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study.
    Tanajewski L; Harris R; Harman DJ; Aithal GP; Card TR; Gkountouras G; Berdunov V; Guha IN; Elliott RA
    BMJ Open; 2017 Jul; 7(6):e015659. PubMed ID: 28679676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised controlled trial of a Mediterranean Dietary Intervention for Adults with Non Alcoholic Fatty Liver Disease (MEDINA): study protocol.
    Papamiltiadous ES; Roberts SK; Nicoll AJ; Ryan MC; Itsiopoulos C; Salim A; Tierney AC
    BMC Gastroenterol; 2016 Feb; 16():14. PubMed ID: 26831892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post hoc analyses of surrogate markers of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis in patients with type 2 diabetes in a digitally supported continuous care intervention: an open-label, non-randomised controlled study.
    Vilar-Gomez E; Athinarayanan SJ; Adams RN; Hallberg SJ; Bhanpuri NH; McKenzie AL; Campbell WW; McCarter JP; Phinney SD; Volek JS; Chalasani N
    BMJ Open; 2019 Feb; 9(2):e023597. PubMed ID: 30803948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis.
    Patel PJ; Banh X; Horsfall LU; Hayward KL; Hossain F; Johnson T; Stuart KA; Brown NN; Saad N; Clouston A; Irvine KM; Russell AW; Valery PC; Williams S; Powell EE
    Intern Med J; 2018 Feb; 48(2):144-151. PubMed ID: 29083080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving access for community health and sub-acute outpatient services: protocol for a stepped wedge cluster randomised controlled trial.
    Harding KE; Watts JJ; Karimi L; O'Reilly M; Kent B; Kotis M; Leggat SG; Kearney J; Taylor NF
    BMC Health Serv Res; 2016 Aug; 16(a):364. PubMed ID: 27506923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected].
    Scorletti E; Bhatia L; McCormick KG; Clough GF; Nash K; Calder PC; Byrne CD;
    Contemp Clin Trials; 2014 Mar; 37(2):301-11. PubMed ID: 24556343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
    Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver fat as a dietary target by Chinese Medical Nutrition Therapy (CMNT) diet for treating type 2 diabetes with non-alcoholic fatty liver disease: study protocol for a randomised controlled trial.
    Luo W; Xiao Z; Yang X; Wu R; Li J; Yu Z; Guo S; Nie B; Liu D
    BMJ Open; 2024 Apr; 14(4):e081263. PubMed ID: 38684277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protocol for a phase IV, open-label feasibility study investigating non-invasive markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fatty liver disease randomised to receiving optimised background therapy (OBT) plus maraviroc or OBT alone.
    Bradshaw D; Gilleece Y; Verma S; Abramowicz I; Bremner S; Perry N
    BMJ Open; 2020 Jul; 10(7):e035596. PubMed ID: 32636281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Daesiho-tang on obesity with non-alcoholic fatty liver disease: a study protocol for a randomised, double-blind, placebo-controlled pilot trial.
    Han K; Kwon O; Park HJ; Jung SY; Yang C; Son CG
    Trials; 2020 Jan; 21(1):128. PubMed ID: 32005283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards collaborative management of non-alcoholic fatty liver disease: a 'real-world' pathway for fibrosis risk assessment in primary care.
    Hayward KL; McKillen BJ; Horsfall LU; McIvor C; Liew K; Sexton J; Johnson AL; Irvine KM; Valery PC; McPhail SM; Britton LJ; Rosenberg W; Weate I; Williams S; Powell EE
    Intern Med J; 2022 Oct; 52(10):1749-1758. PubMed ID: 34139066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a moderately carbohydrate-restricted diet on liver enzymes, steatosis and fibrosis in normal-weight individuals with non-alcoholic fatty liver disease: study protocol for a parallel randomised controlled clinical trial.
    Dashti F; Alavian SM; Sohrabpour AA; Mousavi SE; Keshavarz SA; Esmaillzadeh A
    BMJ Open; 2023 Apr; 13(4):e063988. PubMed ID: 37117000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
    Estes C; Anstee QM; Arias-Loste MT; Bantel H; Bellentani S; Caballeria J; Colombo M; Craxi A; Crespo J; Day CP; Eguchi Y; Geier A; Kondili LA; Kroy DC; Lazarus JV; Loomba R; Manns MP; Marchesini G; Nakajima A; Negro F; Petta S; Ratziu V; Romero-Gomez M; Sanyal A; Schattenberg JM; Tacke F; Tanaka J; Trautwein C; Wei L; Zeuzem S; Razavi H
    J Hepatol; 2018 Oct; 69(4):896-904. PubMed ID: 29886156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Multi-Parametric Magnetic Resonance Imaging in Standard of Care for Nonalcoholic Fatty Liver Disease: Protocol for a Randomized Control Trial.
    Tonev D; Shumbayawonda E; Tetlow LA; Herdman L; French M; Rymell S; Thomaides-Brears H; Caseiro-Alves F; Castelo-Branco M; Ferreira C; Coenraad M; Lamb H; Beer M; Kelly M; Banerjee R; Dollinger M;
    JMIR Res Protoc; 2020 Oct; 9(10):e19189. PubMed ID: 33104014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Gold Coast Integrated Care for patients with chronic disease or high risk of hospitalisation through a non-randomised controlled clinical trial: a pilot study protocol.
    Scuffham PA; Mihala G; Ward L; McMurray A; Connor M
    BMJ Open; 2017 Jul; 7(6):e016776. PubMed ID: 28674147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol.
    Lambert JE; Parnell JA; Eksteen B; Raman M; Bomhof MR; Rioux KP; Madsen KL; Reimer RA
    BMC Gastroenterol; 2015 Dec; 15():169. PubMed ID: 26635079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.